

# Morning Wrap

## Today's Newsflow

Select headline to navigate to article

**Diageo** Self-help and cash generation to the fore as external backdrop remains subdued into FY26

**IAG** No change in expectations but we move to HOLD

**Wizz Air** May traffic stats

## Equity Research

03 Jun 2025

08:44

## Upcoming Events

## Company Events

03-Jun	FD Technologies; FY25 Results
5-Jun	Wizz Air; FY25 Results
10-Jun	Bellway; Q325 Trading Update

## Economic Events

### Ireland

05-Jun	GDP
	ILO Unemployment Rate
09-Jun	Industrial Production
	Live Register

### United Kingdom

04-Jun	CIPS Composite PMI
	CIPS Services PMI
05-Jun	CIPS Construction PMI
10-Jun	ILO Unemployment Rate

## Goodbody Capital Markets

Equity Research +353 1 6419221

Equity Sales +353 1 6670222

Bloomberg RESP GDSE<GO>

## Diageo Self-help and cash generation to the fore as external backdrop remains subdued into FY26

We update our DGE model following its recent Q3 trading update and Guinness deep-dive event. We keep our earnings estimates broadly unchanged as organic downgrades for FY26 (from +3.4%/+4.2% organic sales/EBIT to +2.7%/+3.5%) are largely offset by FX tailwinds. Following +5.9% organic sales growth in Q3 (+2% ex-tariff phasing), we model -0.6% decline in Q4 – this drives FY25 organic sales +1.6% and organic EBIT -0.9% to \$5,701m with adj EPS -8.5% to \$1.64.

**Recommendation: Hold**  
**Closing Price: £19.88**

Fintan Ryan  
+44 74 078 73369  
fintan.ryan@goodbody.ie

While performance in ~1/4 of the portfolio is robust (Tequila at c.15% sales, Guinness at c.10%), the rest of the portfolio is modest at best, impacted by myriad factors across DGE's key geographies (e.g. affordability, abstinence, tariffs). We see some signs of green shoots for DGE based on an improving launch pipeline and resilient market shares, but for the time being, we expect subdued markets to persist into FY26. With this in mind, we welcome management's greater emphasis on costs (c.\$500m 3-year gross savings under the Accelerate program) and cash (>\$3bn FCF per annum commitment from FY26). Details on delivery and phasing will come with FY25 results on 5 August.

For now, we stay HOLD as it will likely take some time for the cost actions to come through and external visibility remains very limited (e.g. US tariffs). Management's deleverage priority from 3.3-3.5x EBITDA in FY25 towards c.2.5x by FY28 likely includes "significant" disposals (we estimate up to c.\$1bn over the period). Shares are -22% ytd with valuation on 16.1x cal.25 P/E trading just back in line with the wider Beverages (17.0x) and Spirits sector averages, also supported by a c.4% dividend and >4% FCF yield

[Home...](#)

## IAG No change in expectations but we move to HOLD

IAG's Q1 EBIT of €198m was ahead of our forecast at €155m. The beat was driven by a stronger than expected revenue performance which was somewhat offset by higher than anticipated costs. We update for results as well as the commentary on capacity (unchanged at c.+3% yoy), costs and capex. We also update for the increased fuel hedge in FY25 and FY26 and the guidance on the fuel bill. Despite highlighting some "recent softness in the US point of sale economy leisure" IAG commented that strength in premium somewhat mitigated that softness and demand continued to be strong in LATAM and Europe. More recently IAG has said that demand is now recovering, and intra-European demand is very strong into summer. At the time of the Q1 results IAG commented that the outlook for FY25 was unchanged.

IAG's did not guide on FY25 RASK. We continue to expect RASK to only be slightly higher yoy (+0.8% yoy). Our ex-fuel CASK assumption is in line with guidance for c.+4% higher yoy. IAG expects the fuel bill to be €7.5bn, we are marginally below this at €7.4bn. Putting it all together, our FY25 EBIT forecast comes in at €4.33bn (was €4.35bn). This compares to FY25 consensus of €4.6bn with our assumption being that others are more bullish on pricing.

**While the pace of earnings growth will be slower in FY25, we still expect cashflow to remain robust, allowing IAG to fund capex, reduce leverage, pay dividends and buy back shares. Our PT remains at 350p, given the recent significant share price appreciation our recommendation moves to HOLD.**

[Home...](#)

## Wizz Air May traffic stats

Wizz Air has reported that it carried 5.66m passengers in May, up +10.3% yoy. Capacity increased by +10.0% yoy to 6.20m seats leaving the load factor at 91.2%, up +0.2ppts on last year's 91.0%. Commenting the traffic stats Wizz Air said that "The increase achieved in passengers carried and the associated lift in loads is very encouraging, particularly given the timing of Easter the month before".

Wizz Air will report FY25 results on Thursday morning. In January, after a period of Euro weakness, Wizz Air guided net income for FY25 between €125m - €175m. This was based on capacity which was anticipated to be flat to up +1%, the load factor being maintained at 92% and RASK up mid-single digits yoy. Ex-fuel CASK was expected to increase by high teens yoy while the fuel CASK was projected to decline by 3%-5% yoy. At the time we reduced our net income forecast to €125m. Subsequently the Euro strengthened and in late March, after factoring in a partial unwind of the Q3 €160m unrealised FX hit and leaving all else broadly unchanged, we increased our net income forecast to €188m.

[Home...](#)

**Recommendation: Hold**  
**Closing Price: £3.35**

Dudley Shanley  
+353-1-641 9174  
dudley.c.shanley@goodbody.ie

**Recommendation: Hold**  
**Closing Price: £15.95**

Dudley Shanley  
+353-1-641 9174  
dudley.c.shanley@goodbody.ie

## Issuer & Analyst Disclosure

### Analyst Certification

The named Research Analyst certifies that: (1) All of the views expressed in this research report accurately reflect my personal views about any and all of the subject securities and issuers. (2) No part of my remuneration was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by me in this report.

### Regulatory Information

Goodbody Stockbrokers UC, trading as Goodbody, is regulated by the Central Bank of Ireland. In the UK, Goodbody is also subject to regulation by the Financial Conduct Authority. Goodbody is a member of Euronext Dublin and the London Stock Exchange. Goodbody is a member of the group of companies headed by AIB Group plc. This publication has been approved by Goodbody. The information has been taken from sources we believe to be reliable, we do not guarantee their accuracy or completeness and any such information may be incomplete or condensed. All opinions and estimates constitute best judgement at the time of publication and are subject to change without notice. The information, tools and material presented in this document are provided to you for information purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or to buy or subscribe for securities.

### Conflicts of Interest

Goodbody has procedures and policies in place to identify and manage any potential conflicts of interest that arise in connection with its research business. Goodbody analysts and other staff who are involved in the preparation and dissemination of research operate and have a management reporting line that is independent to its business. Information barriers are in place between the Corporate Finance arm and the Research arm to ensure that any confidential and or price sensitive information is handled in an appropriate manner.

Our Investment Research Conflicts of Interest Policy is available at [Conflicts of Interest](#)

Investors should be aware, that, where appropriate, research may be disclosed to the issuer(s) in advance of publication, in order to correct factual inaccuracies only and not to materially amend the research in any way. Goodbody is satisfied that it has operational procedures in place, which ensure that such disclosures will not compromise the report's objectivity.

The list of companies for which Goodbody acts as market maker and on which it provides research, is available at [Regulatory Disclosures](#)

## Other disclosures

We would like to inform you that Dudley Shanley holds shares in Wizz Air

A description of this company is available at [Company Descriptions](#)

All prices used in this report are as at close of business of the previous working day unless otherwise indicated.

The time of publication of the report is Irish Standard Time (UTC +1), which accounts for transitions between IST and GMT (i.e. daylight saving time).

A summary of our standard valuation methods are available at [Valuation Methodologies](#)

A summary of share price recommendations and whether material investment banking services have been provided to these companies is available at [Regulatory Disclosures](#)

Other important disclosures are available at [Regulatory Disclosures](#)

Goodbody updates its recommendations on a regular basis. A breakdown of all recommendations provided by Goodbody is available at [Regulatory Disclosures](#) Where Goodbody has provided investment banking services to an issuer, details of the proportion of buys, holds and sells attributed to that issuer will also be included. This is updated on a quarterly basis.

## Recommendation Definitions

Goodbody uses the terms "Buy", "Sell" and "Hold". The term "Buy" means that the analyst expects the security to appreciate in excess of 10% over a twelve month period. The term "Sell" means that the security is expected to decline in excess of 10% over the next twelve months. The term "Hold" means that the analyst expects the security to neither appreciate more than 10%, or depreciate more than 10% over the next twelve months.

On 26th November, 2012, the terms "Add" and "Reduce" were removed from the Recommendation Definitions and both were replaced with the "Hold" recommendation. Any Previous Recommendation that refers to either an "Add" means that the analyst expected the security to appreciate by up to 15% over a twelve month period. Any Previous Recommendation to "Reduce" means that the analyst expected the security to decline by up to 15% over the next twelve months.

In the event that a stock is delisted the firm will automatically cease coverage. If however the firm ceases to cover a stock for any other reason the firm will disclose this fact.

## Distribution of Research to US Investors

Goodbody Stockbrokers UC acts as a market maker and distributes investment research to US major institutional investors and all transactions by US persons involving securities of companies discussed in reports distributed by Goodbody Stockbrokers UC are to be effected via Goodbody Securities, Inc. ('GSI'), a member firm of FINRA and SIPC. GSI is an affiliate of Goodbody Stockbrokers UC and does not act as a market-maker or maintain any positions in any security.

Details of all such positions that are the subject of the research are disclosed in the research reports and at [www.goodbody.ie/legal-and-regulatory-disclosures/](http://www.goodbody.ie/legal-and-regulatory-disclosures/). This information was current as of the last business day of the month preceding the date of the report.

An affiliate of GSI may have acted, in the past 12 months, as lead manager/co-lead manager of a publicly disclosed offer of the securities in this company. Investors should be aware that an affiliate of GSI may have provided investment banking or non-investment-banking services to, and received compensation from this company in the past 12 months or may provide such services in the next three months. The term investment banking services includes acting as broker as well as the provision of corporate finance services, such as underwriting and managing or advising on a public offer.

Estimates/forecasts developed by Goodbody Research may not be met. Additional information is available, upon request to Goodbody Research, about the bases and assumptions behind the conclusions reached in Research reports.

## Disclaimer

While all reasonable care has been taken in the production and dissemination of this report it is not to be relied upon in substitution for the exercise of independent judgement. Nothing in this report constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to your individual circumstances, or otherwise constitutes a personal recommendation to you.

Private customers having access, should not act upon it in anyway but should consult with their independent professional advisors. The price, value and income of certain investments may rise or may be subject to sudden and large falls in value. You may not recover the total amount originally invested. Past performance should not be taken as an indication or guarantee of future performance; neither should simulated performance. The value of securities may be subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities.

All material presented in this report, unless specifically indicated otherwise is copyright to Goodbody. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of Goodbody.